CANbridge Pharmaceuticals Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Lee's Pharmaceutical Holdings Ltd.

TOT BIOPHARM International Co. Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Charmacy Pharmaceutical Co., Ltd.

Antengene Corp. Ltd.

Clover Biopharmaceuticals Ltd.

China Biotech Services Holdings Ltd.

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

CANbridge Pharmaceuticals Inc.

Lansen Pharmaceutical Holdings Ltd.

Fusen Pharmaceutical Co., Ltd.

Why is CANbridge Pharmaceuticals Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 27.77% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -49.26

Flat results in Jun 25

CASH AND EQV(HY) Lowest at HKD 2.15 MM
DEBT-EQUITY RATIO (HY) Highest at -8.07 %
INVENTORY TURNOVER RATIO(HY) Lowest at 1.35 times

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 1770.75%, its profits have risen by 1.8%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CANbridge Pharmaceuticals Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

CANbridge Pharmaceuticals Inc.

1770.75%

4.26

166.30%

Hang Seng Hong Kong

8.25%

0.41

19.93%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-17.07%

EBIT Growth (5y)

27.77%

EBIT to Interest (avg)

-49.26

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.07

Sales to Capital Employed (avg)

9.42

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-1.95

EV to EBIT

-2.32

EV to EBITDA

-2.37

EV to Capital Employed

-2.16

EV to Sales

69.69

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -50.7% (YoY

OPERATING PROFIT(Q)

Highest at HKD -38.09 MM

OPERATING PROFIT MARGIN(Q)

Highest at -159.38 %

PRE-TAX PROFIT(Q)

Highest at HKD -43.61 MM

NET PROFIT(Q)

Highest at HKD -43.61 MM

EPS(Q)

Highest at HKD 0.15

-8What is not working for the Company

CASH AND EQV(HY)

Lowest at HKD 2.15 MM

DEBT-EQUITY RATIO (HY)

Highest at -8.07 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.35 times

NET SALES(Q)

Lowest at HKD 23.9 MM

Here's what is working for CANbridge Pharmaceuticals Inc.

Operating Profit

Highest at HKD -38.09 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at -159.38 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at HKD -43.61 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Pre-Tax Profit

At HKD -43.61 MM has Grown at 83.73%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

Highest at HKD -43.61 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

Net Profit

At HKD -43.61 MM has Grown at 83.73%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS

Highest at HKD 0.15

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Raw Material Cost

Fallen by -50.7% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for CANbridge Pharmaceuticals Inc.

Net Sales

At HKD 23.9 MM has Fallen at -50.77%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (HKD MM)

Net Sales

Lowest at HKD 23.9 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (HKD MM)

Cash and Eqv

Lowest at HKD 2.15 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -8.07 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.35 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio